CION Ameerpet
A preventive mastectomy removes breast tissue before cancer develops, to lower the risk in women at very high risk — such as BRCA1, BRCA2 or PALB2 carriers. For the right person it can cut breast cancer risk by up to 90–95%, but it is a major, deeply personal decision that is never automatic. CION's tumor-board-led team in Hyderabad helps you weigh it calmly against safer alternatives — with genetic counselling first and a free first consultation.
A risk-reducing mastectomy — also called a preventive or prophylactic mastectomy — is surgery to remove breast tissue in a woman who does not have breast cancer, in order to lower the chance she ever develops it. It is different from a mastectomy done to treat an existing cancer. Here the goal is prevention, so it is only considered for women whose lifetime risk is genuinely high.
There are two situations. A bilateral risk-reducing mastectomy removes tissue from both breasts in a high-risk woman who has never had breast cancer. A contralateral risk-reducing mastectomy removes the healthy second breast in a woman already treated for cancer in one breast, when her risk in the remaining breast is high. Surgery is almost always paired with a conversation about breast reconstruction, which can be done at the same time or later.
One honest point matters above all: surgery lowers risk dramatically but cannot remove every cell of breast tissue, so a small risk always remains. That is why this is a careful, counselling-led decision — not a quick fix — and why CION reviews every case at our tumor board before any surgery is planned.
Done before any cancer exists, to lower future risk — not to remove a known tumour.
Both breasts in a high-risk woman, or the healthy second breast after cancer in the other.
Not all breast tissue can be removed, so surgery reduces but never fully eliminates risk.
For women with a BRCA1 or BRCA2 mutation, a bilateral risk-reducing mastectomy lowers breast cancer risk by about 90–95% — but it cannot remove every cell of breast tissue, so a small residual risk always remains and lifelong follow-up continues. Sources: NCCN Genetic/Familial High-Risk Assessment (Breast); SEER.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Preventive mastectomy is reserved for women at clearly elevated risk — not for average risk, and not as routine reassurance. International guidelines (NCCN, ESMO) and Indian hereditary-cancer practice point to the groups below. Importantly, being in one of these groups does not mean surgery is recommended; it means the option is worth discussing carefully with a specialist and a genetic counsellor before deciding anything.
Women with a confirmed pathogenic BRCA1 or BRCA2 mutation carry a roughly 55–72% lifetime breast cancer risk. They are the group most often counselled about preventive mastectomy — but the choice still depends on age, family plans and personal wishes, and many opt for intensive surveillance instead.
PALB2 is now recognised as a high-risk gene, with an estimated 40–60% lifetime risk that approaches BRCA levels in families with several affected relatives. TP53 (Li-Fraumeni syndrome) carries a very high, often very early risk. These results are interpreted gene-by-gene, never as a single rule.
Several close relatives diagnosed with breast cancer — especially before age 50 — or ovarian, pancreatic or prostate cancer on the same side of the family, can place a woman at high risk even when a specific mutation is not found. Risk-assessment tools and counselling clarify how high.
Women who had radiation therapy to the chest before about age 30 (for example for Hodgkin lymphoma) have a substantially raised breast cancer risk and may be counselled about preventive options alongside enhanced screening.
Lobular carcinoma in situ (LCIS) is not cancer, but it is a marker of higher future risk. Combined with a strong family history or a high-risk gene, some women discuss preventive surgery — though most are managed with surveillance and medication first.
A woman treated for breast cancer in one breast who also carries a high-risk gene or strong family history may consider removing the healthy second breast (contralateral risk-reducing mastectomy) to lower the chance of a new, separate cancer.
The numbers are striking, and worth reading carefully. For women with a BRCA1 or BRCA2 mutation, a bilateral risk-reducing mastectomy lowers breast cancer risk by about 90–95%. In practical terms, a lifetime risk of around 69–72% can fall to roughly a 1–5% residual risk. For women with a strong family history, risk reduction is on the order of up to 90%. Removing the healthy second breast after a first cancer lowers the chance of a new cancer there by a similar 90–95%.
Two honest points keep this in perspective. First, a small risk always remains, because no surgery can remove every cell of breast tissue — so women still need a clinical follow-up plan. Second, while risk reduction is large, a clear survival advantage from preventive mastectomy has been shown in only some groups (recent data suggest a benefit mainly in BRCA1 carriers), and not for everyone. That is exactly why the decision is weighed against age and life stage: a younger carrier has more years of risk to prevent, while for an older woman, surveillance may serve just as well. CION's tumor board frames these figures around your situation, not a generic statistic.
Bilateral surgery typically cuts a 69–72% lifetime risk to roughly a 1–5% residual risk.
Women at high risk from family history alone see substantial reduction, individually assessed.
Large risk reduction does not always mean longer life — timing and gene type matter, and we explain this honestly.
“Preventive mastectomy” is not one operation — it is a family of techniques, and the right one depends on your anatomy, your gene result and your wishes about reconstruction. The amount of tissue removed is similar across them; what differs is how much skin and the nipple are preserved, which affects the look and feel of a reconstructed breast. Reconstruction can be immediate (in the same operation) or delayed, and uses either implants or your own tissue. Your surgical, plastic and oncology teams plan this together — at CION, as one tumor board.
Removes the whole breast including the nipple and areola, but not the underarm lymph nodes (which are left alone in preventive surgery). It offers the most complete tissue removal and is sometimes preferred for the highest-risk genes, with reconstruction planned afterwards.
Removes the breast tissue and the nipple-areola while preserving the breast skin envelope. Keeping the natural skin makes immediate reconstruction look more natural, with fewer and better-hidden scars, while still removing the great majority of at-risk tissue.
Preserves the skin and the nipple-areola, removing the tissue beneath. It gives the most natural cosmetic result and is widely used for risk reduction in suitable BRCA carriers, though a tiny amount of tissue behind the nipple remains, so candidacy is decided case by case.
Rebuilds the breast shape using a tissue expander followed by a silicone or saline implant. It avoids a second surgical site on the body, with a shorter operation and recovery, and is a common choice when both breasts are reconstructed together.
Uses your own skin, fat and sometimes muscle — often from the abdomen — to rebuild the breast. It can give a softer, more natural result that ages with you and avoids an implant, but involves a longer operation, a second healing site and a longer recovery.
Reconstruction can be done in the same operation as the mastectomy (immediate) or months to years later (delayed). Immediate reconstruction means waking with a breast mound and fewer operations; delayed gives more time to decide. The right timing is individual and discussed in advance.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Free first consultation. Confidential, counselling-led guidance at CION Cancer Clinics, Hyderabad. Call us: 1800-202-8726.
Surgery is never the only path — and for many high-risk women it is not even the first choice. The right plan depends on your gene, age, family plans and how you feel about the options. At CION these alternatives are weighed at the tumor board alongside surgery, so you see the full picture before deciding anything. Crucially, choosing surveillance is not “doing nothing”: it is an active, structured plan to catch any cancer at its earliest, most treatable stage.
A structured programme of breast MRI plus mammography, usually starting around age 25–30 (earlier for TP53), often alternating so you are imaged about every six months, with clinical breast exams. It does not lower risk, but it aims to find any cancer very early, when outcomes are best — and many BRCA carriers choose it over surgery.
For some women, preventive (chemoprophylaxis) medicines such as tamoxifen, raloxifene or aromatase inhibitors can lower breast cancer risk, particularly for hormone-receptor-positive disease. Suitability, benefits and side-effects are decided individually with your oncologist — it is not right for everyone.
Removing the ovaries and fallopian tubes is recommended for BRCA carriers, usually around age 35–40 after childbearing, to lower ovarian cancer risk substantially. In premenopausal women it can also modestly lower breast cancer risk. It is a separate decision from breast surgery but often discussed together.
Maintaining a healthy weight, regular activity and limiting alcohol all modestly lower risk, and matter whichever path you choose. Above all, high-risk care is a lifelong, structured follow-up with your team — not a one-off appointment — so the plan adapts as you age.
This is one of the hardest choices in breast care, and there is no single right answer — only the right answer for you. A preventive mastectomy is permanent, so it deserves an unhurried, fully informed decision. We encourage every woman to take her time, involve the people she trusts, and seek a second opinion if she wants one. There is no pressure at CION, ever.
The physical realities are important to understand in advance: recovery typically takes about three to four weeks for the mastectomy alone, and up to about eight weeks when reconstruction is involved. Most women have permanent loss of breast sensation and cannot breastfeed afterwards, and there are the usual surgical risks of bleeding, infection and complications. The emotional side is just as real — feelings about body image, femininity and intimacy are common and valid. The reassuring evidence is that, with good counselling beforehand, anxiety usually falls after surgery and quality of life is maintained or improves for a large majority of women. CION's psycho-oncology support is part of the journey, not an afterthought.
There is no deadline. Involve loved ones, ask every question, and seek a second opinion if you wish.
About 3–4 weeks recovery (up to ~8 with reconstruction); expect permanent loss of breast sensation and breastfeeding.
Body-image and intimacy concerns are normal; CION's psycho-oncology team supports you before and after.
At CION Cancer Clinics, a decision this big is never left to one doctor or one rushed appointment. As a woman-headed, tumor-board-led organisation, we built a pathway that is calm, transparent and counselling-first — because a preventive choice should be made for healing and peace of mind, not from fear. We begin with genetic counselling, lay out every option (surveillance, medication and surgery) honestly, and only proceed if and when it is genuinely right for you. Every consultation runs a full 45 minutes, with no rushed decisions and no unnecessary tests.
With 150+ years of combined oncology experience, 17 super-specialist oncologists and 35+ centres across Telangana and AP, we have guided more than 15,000 patients and families — earning a 4.8/5 Google rating across our centres. For breast cancer, CION's outcomes lead the national average: a 96.9% one-year survival rate at CION versus 85.4% nationally*. Whichever path you choose, your first consultation is free.
*1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP). Figures are population-level and not a guarantee of individual outcome.
Genetic counselling and a full options review before any surgery is ever planned — the choice stays yours.
Surgical, medical and radiation oncologists plus plastic surgery review your case together — not one opinion.
No rushed decisions, no unnecessary tests — decisions for healing, not billing.
Emotional and body-image support is built into the journey, before and after any surgery.
Hear from high-risk women and BRCA carriers who weighed their options with CION's counselling-led pathway.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.A preventive mastectomy — also called a risk-reducing or prophylactic mastectomy — is surgery to remove breast tissue in a woman who does not have breast cancer, to lower her chance of ever developing it. It is only considered for women at genuinely high risk, such as BRCA1, BRCA2 or PALB2 carriers, those with a very strong family history, or women who had chest radiation when young. It can be bilateral (both breasts) in a high-risk woman, or contralateral (the healthy second breast) in a woman already treated for cancer in one breast. Surgery is usually paired with a discussion about breast reconstruction. It is always a personal, counselling-led decision, never automatic.
It is reserved for women at clearly high risk — not average risk. The groups most often counselled about it are confirmed BRCA1 or BRCA2 carriers (roughly 55–72% lifetime risk), and carriers of other high-risk genes such as PALB2 or TP53. It is also discussed with women who have a very strong family history of breast, ovarian, pancreatic or prostate cancer, those who had chest radiation before about age 30, and some women with LCIS plus other risk factors. Being in one of these groups does not mean surgery is recommended — it means the option is worth discussing carefully with a specialist and a genetic counsellor, alongside surveillance and medication, before any decision.
For women with a BRCA1 or BRCA2 mutation, a bilateral risk-reducing mastectomy lowers breast cancer risk by about 90–95% — in practice taking a lifetime risk of around 69–72% down to roughly a 1–5% residual risk. For women at high risk from a strong family history, the reduction is on the order of up to 90%. Removing the healthy second breast after a first cancer lowers the chance of a new cancer there by a similar amount. Two honest points: a small risk always remains because not all breast tissue can be removed, so follow-up continues; and large risk reduction does not always translate into longer survival, which depends on your age and gene type.
There are three main surgical techniques. A total (simple) mastectomy removes the whole breast including the nipple. A skin-sparing mastectomy keeps the breast skin envelope for a more natural reconstruction. A nipple-sparing mastectomy preserves the skin and nipple, giving the most natural cosmetic result — widely used for suitable BRCA carriers. Reconstruction can be immediate (same operation) or delayed, and uses either implants (a tissue expander then a silicone or saline implant) or your own tissue, often from the abdomen, which gives a softer, more natural result but a longer recovery. At CION, surgical, plastic and oncology teams plan the technique and timing together for your case.
Surgery is not the only option, and for many high-risk women it is not the first choice. Enhanced surveillance — a structured programme of breast MRI plus mammography, usually from age 25–30 and often every six months — aims to catch any cancer at its earliest, most treatable stage. Risk-reducing medication such as tamoxifen, raloxifene or aromatase inhibitors can lower risk for some women. For BRCA carriers, removing the ovaries and tubes (around age 35–40 after childbearing) lowers ovarian cancer risk and can modestly lower breast risk too. Healthy weight, activity and limiting alcohol help whichever path you choose. CION weighs all of these against surgery at the tumor board so you see the full picture.
Recovery depends on whether reconstruction is done at the same time. For the mastectomy alone, most women recover over about three to four weeks. With immediate reconstruction, recovery can take up to about eight weeks, and the operation itself is longer. You can expect soreness, temporary drains, and activity restrictions in the first weeks, with a gradual return to normal life. Most women have permanent loss of breast sensation and cannot breastfeed afterwards. As with any surgery, there are risks of bleeding, infection and complications. Your team will give you a clear, personalised recovery plan, and CION's nursing and psycho-oncology support continues through your healing.
Yes — and that is completely normal. A preventive mastectomy is permanent and touches on body image, femininity and intimacy, so strong feelings are valid and expected. There is no deadline to decide, and we encourage you to take your time, involve people you trust, and seek a second opinion if you wish. The reassuring evidence is that, with good counselling beforehand, anxiety usually falls after surgery and quality of life is maintained or improves for a large majority of women. At CION, psycho-oncology support is built into the pathway from the very first conversation — before any decision is made — not added on at the end.
Start with a free first consultation — book online or call CION at 1800-202-8726. Your first appointment is an unhurried, 45-minute counselling conversation that reviews your gene result or family history and lays out every option, with no pressure toward surgery. If genetic testing is needed first, BRCA panel testing in Hyderabad typically costs in the region of ₹16,000–₹25,000, and CION's counsellors explain this before anything is ordered. Surgical costs depend on the technique and whether reconstruction is included, and we give a clear, transparent estimate in advance — no unnecessary tests, no hidden charges. Every case is reviewed by our tumor board so your plan is genuinely personalised.